Stock A002720 KUKJE PHARMA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Kukje Pharma Co., Ltd.

Equities

A002720

KR7002720001

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 30/05/2024 BST 		5-day change 1st Jan Change
4,745 KRW +0.74% Intraday chart for Kukje Pharma Co., Ltd. -1.86% -19.85%
05-16 Kukje Pharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-18 Kukje Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 74,643 81,078 176,865 112,861 106,115 119,890
Enterprise Value (EV) 1 96,777 106,601 210,728 140,944 129,152 139,920
P/E ratio 33.4 x -17 x 80.3 x -72.2 x 29.9 x -14.2 x
Yield 0.7% - - - - -
Capitalization / Revenue 0.69 x 0.73 x 1.36 x 0.94 x 0.84 x 0.89 x
EV / Revenue 0.9 x 0.96 x 1.62 x 1.18 x 1.02 x 1.03 x
EV / EBITDA 16.1 x 12.1 x 21.8 x 51.4 x 13.2 x 63.2 x
EV / FCF 11.6 x 29.2 x -51.3 x 25.7 x 36.9 x 16.4 x
FCF Yield 8.6% 3.42% -1.95% 3.89% 2.71% 6.11%
Price to Book 1.07 x 1.33 x 2.51 x 1.65 x 1.43 x 1.41 x
Nbr of stocks (in thousands) 20,236 20,272 20,272 20,265 20,258 20,252
Reference price 2 3,689 4,000 8,725 5,569 5,238 5,920
Announcement Date 13/03/19 10/03/20 17/03/21 10/03/22 16/03/23 18/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 107,681 111,122 130,395 119,746 126,583 135,373
EBITDA 1 6,028 8,813 9,667 2,743 9,760 2,215
EBIT 1 3,287 5,562 6,041 -1,676 5,273 -1,989
Operating Margin 3.05% 5.01% 4.63% -1.4% 4.17% -1.47%
Earnings before Tax (EBT) 1 2,830 121.4 5,594 -1,110 4,745 -6,681
Net income 1 2,193 -4,761 2,203 -1,559 3,557 -8,415
Net margin 2.04% -4.28% 1.69% -1.3% 2.81% -6.22%
EPS 2 110.3 -235.0 108.7 -77.10 175.2 -415.5
Free Cash Flow 1 8,323 3,645 -4,106 5,485 3,504 8,550
FCF margin 7.73% 3.28% -3.15% 4.58% 2.77% 6.32%
FCF Conversion (EBITDA) 138.08% 41.36% - 199.94% 35.9% 386.02%
FCF Conversion (Net income) 379.59% - - - 98.5% -
Dividend per Share 2 25.92 - - - - -
Announcement Date 13/03/19 10/03/20 17/03/21 10/03/22 16/03/23 18/03/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 22,135 25,523 33,862 28,084 23,037 20,030
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 3.672 x 2.896 x 3.503 x 10.24 x 2.36 x 9.043 x
Free Cash Flow 1 8,323 3,645 -4,106 5,485 3,504 8,550
ROE (net income / shareholders' equity) 3.2% -7.35% 3.34% -2.24% 4.97% -10.6%
ROA (Net income/ Total Assets) 1.59% 2.67% 2.69% -0.73% 2.38% -0.83%
Assets 1 137,624 -178,612 81,747 212,445 149,179 1,014,856
Book Value Per Share 2 3,455 3,006 3,477 3,384 3,656 4,194
Cash Flow per Share 2 184.0 367.0 198.0 388.0 273.0 523.0
Capex 1 3,026 5,887 11,600 1,892 1,259 1,046
Capex / Sales 2.81% 5.3% 8.9% 1.58% 0.99% 0.77%
Announcement Date 13/03/19 10/03/20 17/03/21 10/03/22 16/03/23 18/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
KUKJE PHARMA CO., LTD. Stock Kukje Pharma Co., Ltd.
-19.85% 69.49M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+15.91% 41.97B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+22.40% 22.34B
SANDOZ GROUP AG Stock Sandoz Group AG
+18.48% 15.25B
CIPLA LIMITED Stock Cipla Limited
+16.12% 14B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+45.12% 12.06B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-9.58% 6.8B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+14.18% 5.49B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A002720 Stock
  4. Financials Kukje Pharma Co., Ltd.